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Abstract 
Two synthetic projects were embarked upon, both fraught with protecting group 
nuance and reaction selectivity. Transformations of the opiate skeleton remain a 
valuable tool for the development of new medicines. Thebaine, a biosynthetic 
intermediate in the expression of morphine, was converted in three steps to 
oripavine through two parallel modes. Through the use of protecting group 
manipulations, two irreversible scaffold rearrangements were avoided during 
aryl methyl ether bond cleavage. This chemistry constitutes a new path in 
manipulations of the morphinan scaffold through protective groups.   
A new compound family, the flacourtosides, contains an unusual cyclohexenone 
fragment. The newly described compounds show in preliminary tests antiviral 
activity against dengue and chikungunya. This aglycone was approached on 
three pathways, all beginning with the chemoenzymatic dihydroxylation of 
benzoic acid. A first attempt from a known vinyl epoxide failed to epimerize and 
cooperate under deprotective conditions. A second and third attempt made use 
of a diastereoselective dihydroxylation reaction, which was critical in reaching 
the correct stereochemistry and oxidation state. The methyl ester of the 
aglycone was prepared, constituting the first synthesis of the non-trivial natural 
product framework. 
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1. INTRODUCTION 
 The production of meaningful quantities of medicines and materials is 
still in development. The science of chemical synthesis remains a fledgling 
endeavor. Extending the evolutionary products of nature to the purposeful 
treatment of the ill is a humanitarian objective and remains a challenging 
scientific pursuit.  
 Described herein are two projects: a relay synthesis of oripavine, which 
serves as an important precursor to pharmaceutical pain-killers and antidotes, 
and the synthesis of a phenolglycoside aglycone which has shown medicinal 
value in the treatment of dengue, chikungunya, and malaria, Figure 1.  
 
Figure 1. Thesis objectives. 
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2. HISTORICAL 
2.1 Opiate-derived pharmaceutical agents 
 The pharmacological effects of opium have been known for millennia, 
and so has the addictive and lethal risk associated with using opium or its 
purified components.1 The anti-nociceptive quality of natural opium alkaloids,2 
Figure 1, and derivatives thereof, Figure 2, continue to have valid medical and 
scientific applications.  
 
Figure 2. Representative opium alkaloids. 
Chemical production of these pharmaceutical agents is dependent on the annual 
opium poppy’s cultivation and alkaloid yield.3 Because total synthesis of these 
complex structures is economically prohibitive,4 harvesting compounds from 
nature and then chemically modifying them for a set purpose is by far the easiest 
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route to a final product.5,6 The final product of interest governs the choice of 
natural starting material and the synthetic route chosen. 
 
Figure 3. Representative semisynthetic opiate drugs. 
 
Generalization of early transformations followed by late-stage divergence to the 
desired drug would constitute an ideal state of the art. When processing 
semisynthetic opiates,5 late-stage divergence in chemical modification is strictly 
better from an economical point of view. Acquiring large quantities of this 
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hypothetical chemical intermediate from natural sources is where thebaine and 
oripavine have their story.  
 When referring to the certain anatomy of the morphinan scaffold, a 
numbering- and ring-lettering system shown below are used, Figure 4. Such a 
diagram assists in communication between researchers as to the exact subtleties 
of a particular opiate-derived substance.  
 
Figure 4. Morphinan numbering system and ring assignment. 
 
The two naturally occurring alkaloids, thebaine 1 and oripavine 2, are produced 
through a long sequence within the poppy, Figure 4, and serve as intermediates 
along the branched biosynthetic pathway to codeine and morphine. Thebaine 
and oripavine may be intercepted along this biosynthetic pathway and then 
subjected to chemical synthesis that produces unnatural opiate drugs.3 These 
derivatives have substantially different pharmacological profiles: some are 
potent analgesics or non-addictive pain-killers, and others even serve as 
therapeutic agents for addiction and/or overdose to other opiates, Figure 3. The 
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natural alkaloid content of P. somniferum (compared to top1 {thebaine oripavine 
poppy 1}) dry straw mass is morphine: 2.4 % (0.05%), codeine 0.1% (0.01%), 
oripavine 0.03% (0.8%), thebaine 0.1% (2.0%).7,8 
 
Figure 5. Biosynthetic intermediates en route to morphine. 
 
The Top1 strain was engineered by way of chemical mutagenesis of the opium 
poppy plant and selected over several generations. The accumulation of 
thebaine and oripavine, instead of codeine and morphine is very useful since 
thebaine and oripavine have no appreciable psychoactive profiles, yet serve as 
indispensable starting materials in the production of any semisynthetics6,9,10 
other than heroin, Figure 5.  
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2.1.1 Thebaine and oripavine as precursors for semisynthesis 
 The inherent reactivity of the dienol ether moiety in 1 and 2 is utilized in 
the production of semisynthetic opiate-derived therapeutic agents. Oxidation or 
Diels-Alder chemistry is easily performed on the C ring of the thebaine/oripavine 
system. Such products may thus be carried onward toward oxymorphone, 
naloxone, buprenorphine, etc.4,6  
 
Scheme 1. Conversion of thebaine to oxycodone. 
a) (i) AcOH, 30% H2O2(aq), rt. (ii) Pd/C, H2 (45 psi), rt, 95% yield (two 
steps). 
 
The C-6-ketone and 14-hydroxyl functional groups that appear in such materials 
as oxycodone are prepared by means of well-documented and predictable 
chemistry, Scheme 1.10,11  
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Scheme 2. Conversion of oripavine to oxymorphone. 
a) (i) AcOOH, AcOH, H2O, rt. (ii) Pd/C, H2 (60 psi), 90 °C, 95% yield (2 
steps). 
 
However, the demethylation of the 3-O- and 17-N-positions are not simple 
operationally, and especially not if preservation of the dienol ether moiety in the 
C ring is intended. 
 The only single step procedure yet disclosed to produce oripavine from 
thebaine was accomplished using L-selectride in THF at reflux, Scheme 3.12 
 
  Scheme 3. Direct conversion of thebaine to oripavine. 
 a) excess L-selectride, THF, reflux, two weeks, 35% yield.  
 
Unfortunately, the high price of L-selectride, the exceedingly long reaction time, 
and the poor yield13 have demanded the search for an alternative. To aggravate 
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the issue, remaining chemical systems to achieve cleavage of an aryl methyl 
ether rely on strongly acidic (Lewis and/or Brønsted) or basic conditions at very 
high temperatures.14 The primary reason for avoidance of acidic demethylation 
of thebaine lies in the prevention of hydrolysis of the vinyl ether to codeinone 
20, or more severe rearrangements, such as the apomorphine rearrangement, 
Path A, Figure 6.15  
 
Figure 6. Acid-catalyzed rearrangements of thebaine/oripavine. 
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Protonation of the E ring’s ether linkage leads to an unraveling of the C and D 
rings by alkyl migration and eventual aromatization to either an apomorphine 21 
or phenanthrene 22 scaffold. Interestingly, the application of the apomorphine 
rearrangement has found use in the preparation of dopaminergic drug, 26, 
development, Scheme 4. First, azodicarboxylate oxidation to 23 and subsequent 
3-O-demethylation according to Rice’s protocol provided 24, the “holy grail” of 
morphinan synthetic intermediates, oripavidine (nororipavine).16  
 
Scheme 4. Synthesis of oripavidine and apomorphine analogue. 
a) DEAD, PhMe, reflux, 67%; b) excess L-selectride, THF, reflux, 64%; c) 
nPrOH, NaHCO3, [Cp*IrCl2]2, μW, 140 °C, 70%; d) MeSO3H, 95 °C, 79%. 
 
 In order to prevent acid-promoted rearrangements of the C ring, two 
schemes were seen as reasonable precedents for implementing reasonable 
protecting strategies (depending on selective and reversible reactivity). Based on 
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Birch’s work, thebaine’s C ring may be complexed as an iron tricarbonyl, Scheme 
5,17 which imparts a reactivity profile similar to an aromatic and/or an aliphatic 
system.  
 
Scheme 5. Dienol ether protection with iron carbonyl.  
a) Fe3(CO)12, C6H6, reflux; or Fe(CO)5, C6H6,UV light. 
 
The iron carbonyl complex may be removed under mild oxidative conditions to 
regenerate the dienol ether in the C ring. 
 Kirby and coworkers explored the use of thioaldehydes with several 
dienes,18 but prominently, thebaine presented an interesting case, in which 
intermediates rearranged upon prolonged heating, Scheme 6.19 The enrichment 
of the thermodynamic product 30 from the initial scalemic product 29 signified a 
reversibility of the  
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Scheme 6. Thioaldehyde-Diels-Alder to thebaine and rearrangements 
thereof. 
a) NEt3, CaCl2·2H2O, [EtOH/C6H6 (1:1)], rt; b) PhMe, reflux, 8 h; c) PhMe, 
reflux, 160 h; d) conc. HCl, reflux.  
 
hetero-Diels-Alder cycloaddition, whereby the thioaldehyde may be trapped 
under certain conditions, Scheme 6. Kirby’s group further explored exchange of 
thioaldehydes from the anthracene-adduct 34 and found that heating the 
sulfoxide 35 led to the transient sulfine (thioaldehyde S-oxide) intermediate 36, 
which cyclized diastereoselectively with thebaine to provide the chiral sulfoxide 
37.20 
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Scheme 7. Sulfine cycloaddition to thebaine. 
a) 28, NEt3, CaCl2·2H2O, [EtOH/C6H6 (1:1)], rt; b) mCPBA, CH2Cl2, rt; c) 
thebaine, C6H6, 80 °C. 
 
The existing literature on reversible cyclohexadiene transformations provided 
valuable insight that would be applied to the 3-O-demethylation of thebaine in 
order to prepare oripavine vide infra, as described in the Discussion Section of 
this thesis. 
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2.2 The use of ipso-diol derived from benzoic acid in organic synthesis 
 As new reaction development slows and complex natural products 
discovery continues, innovative alternative chemical processes have emerged. 
The use of biochemical metabolites in synthesis has been gaining traction of the 
past couple of decades. Some microorganisms have evolved to metabolized 
aromatic compounds in their environment. Mutant strains of bacteria have been 
engineered to accumulate diene-diol chemical entities. Ralstronia eutrophus B9 
is such a mutant in which (dihydroxybenzoate) DHB dehydrogenase is no longer 
expressed, Figure 7.21,22 Isolation of this chiron 4, is an excellent starting point for 
synthesis of more complex molecules.23  
 
Figure 7. Microbial pathway for benzoic acid degradation. 
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Though the metabolite was characterized over 40 years ago, it has not been 
utilized in total synthesis campaigns until the past 10 years.24  
 
2.2.1 Enantioselective natural product syntheses from benzoic acid  
 The first and most complex incorporation of the unique ipso-diol 4 into a 
synthetic sequence was accomplished by Myers and co-workers in their total 
synthesis of (–)-tetracycline, Schemes 8 and 9,25,26 and analogs thereof. First, 
hydrogen-bonding-directed epoxidation furnished 40, followed by carboxylate 
protection as the methyl ester, and TBS protection interrupted by a Payne 
rearrangement leading to the chiral electrophile 41. Addition of the lithiated 
isoxazole 42 to the methyl ester 41 provided the ketone 43. An unusual 
Sommelet-Hauser rearrangement of 43 closed the A ring to supply 44 with 
correct stereochemistry. Reductive transposition, followed by deprotection of 45 
and subsequent oxidation provided enone 46. Activation with pyridinium 
tribromide and displacement with thiophenol provided the activated 
cycloaddition partner 47, Scheme 8. The mercapto enone and benzocyclobutane 
48 were heated together without solvent to form the linear tetracyclic core 49, 
Scheme 9. 
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Scheme 8. Total synthesis of tetracycline from benzoic acid diol. Part 1. 
a) mCPBA, EtOAc, 83%; b) (i) TMSCHN2, Et2O; (ii) TBSOTf, NEt3, 70% (2 
steps); c) THF, –78 °C; d) (i) LiOTf, PhMe, 60 °C; (ii) TFA, CH2Cl2, 62% (2 
steps); e) NBSH, DEAD, PPh3, PhMe, 74%; f) (i) HCl, MeOH; IBX, DMSO, 
66% (2 steps); g) (i) HPyr·Br3, CH2Cl2; (ii) PhSH, DBU, DMF, 66% (2 steps); 
h) neat, 85 °C. 
 
The silyl-protected alcohol 49 was unmasked and then oxidized to yield the 
diketone, whose sulfide was oxidized with a peroxyacid and released upon 
heating. On exposure to air, napthol 52 was spontaneously oxidized to the 
16 
 
hydroperoxide derivative 53, which was then immediately reduced under 
hydrogen atmosphere to yield tetracycline 54, identical in properties to natural 
tetracycline.  
 
Scheme 9. Total synthesis of tetracycline from benzoic acid diol. Part 2. 
i) NEt3·3HF, THF, 23 °C, 76%; j) IBX, DMSO, 35 °C, 77%; k) TFA, mCPBA, 
CH2Cl2, –78 °C to 35 °C; l) O2, spontaneous; m) Pd/C, H2, dioxane, 42% 
from 51 (sulfide-diketone). 
 
In 2011, Lewis and coworkers27,28 showed that the cyclohexadiene moiety in 55 
could be retained through a series of reductions and oxidations. The dienone, 59, 
which upon oxidative cleavage of the iron tricarbonyl led to 60, and its 
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spontaneous dimerization to provide the final product 61, whose attainment 
served to establish the absolute stereochemistry of the natural product, (–)-
grandifloracin. 
 
Scheme 10. Total synthesis of ent-grandifloracin.  
a) TMSCHN2, MeOH, PhH, 90%; b) Fe2(CO)9, THF, 77%; c) DIBAL, THF, 
CH2Cl2, –78 °C to 20 °C; d) BzCl, collidine, THF, 57% (two steps); e) MnO2, 
4Å MS, CH2Cl2, 78%; f) CAN, acetone, 0 °C, 34%. 
 
Through a similar pattern recognition of dimerization, the unsaturated ketol 63 
was prepared by the Hudlicky group29 through hydrogenation and subsequent 
oxidation. When exposed to base, ketol 63 furnished stereoselectively the 
spiroketal dimer, namely idesolide 64.  
18 
 
 
Scheme 11. Total synthesis of idesolide. 
a) PAD, AcOH, MeOH, 0 °C, 40%; b) IBX, DMSO, 59%; c) NaHCO3, CHCl3, 
43%. 
This chemoenzymatic approach represents the best synthesis so far of 
idesolide,29 which possesses many interesting biological activities.30,31 
 In addition to the above total syntheses, below are some other novel 
molecules that were prepared from the ipso-diol 4.32,33 The polyhydroxylated 
pyrrolidine 65 was prepared as a new nucleoside fragment as an avenue for 
antiviral therapy,32 and the inositol-amino acid 66 was prepared out of interest 
for the fusion of two distinct biological motifs.34 The cyclohexenol 67 was 
prepared by way of an oxygen Diels-Alder.35 These chemical entities would 
otherwise be very difficult or impossible if it were not for the chemoenzymatic 
first step. 
 
 Figure 8. Unusual synthetic products from chemoenzymatic syntheses. 
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 Phenolic glycosides bearing highly oxygenated cyclohexenones have 
recently been demonstrated to participate in the treatment of malaria, 
chikungunya, and dengue.36,37 Even though the compound, xylosmin 5, has been 
known for over 20 years,38 and several recent discoveries of similar compounds 
68 and 69 have demonstrated their niche biological potential as therapeutics,39 
no synthesis of the unusual cyclohexenone fragment has yet been reported. 
 
Figure 9. Natural products bearing the highly oxidized cyclohexenone-
carboxylate fragment.  
 
The unusually oxygenated cyclohexenone in xylosmin inspired a project to 
synthesize the fragment, as will be described in the following discussion. 
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3. RESULTS & DISCUSSION 
3.1 O-Demethylation of thebaine to oripavine 
 In an effort to generalize the preparation of semisynthetic orvinol-
derived pharmaceuticals from the readily available alkaloid thebaine, two 
strategies of protection, demethylation, and deprotection were used to produce 
oripavine. 
3.1.1 C-Ring protection with iron carbonyl 
 Birch’s protocol17,40 was used to generate thebaine-iron-tricarbonyl 
complex, isolated in nearly quantitative yield by Dr. Šnajdr. From this point many 
chemical conditions were applied to unmasking the free phenol of the A ring. To 
do so, acidic conditions were chosen as basic (nucleophilic) systems14 were 
incompatible with the iron tricarbonyl functionality, Table 1.  
 
Entry Conditions Result 
1 BBr3, CH2Cl2, 0 °C41,42 83% 
2 BF3·SMe2, CH2Cl2 0 °C43 83% 
3 MeSO3H, methionine, 50 °C44 67% 
4 9-I-9-BBN, CH2Cl2, rt45 70% 
21 
 
5 NbCl5, CH2Cl2, rt46,47 decomp. 
6 NbCl5, DCE, reflux46 decomp. 
7 HBr (conc.), reflux no rxn 
8 TMSI, MeCN, reflux48 no rxn 
9 TMSCl, NaI, MeCN, reflux48 no rxn 
10 CeCl3·7H2O, NaI, MeCN, reflux49 no rxn 
 
Table 1. O-Demethylation Studies of thebaine-iron-carbonyl complex. 
 
Standard aryl methyl ether dealkylation conditions were used at first, i.e. BBr3, 
with a few more unusual ones, MeSO3H/methionine, or 9-I-9-BBN surfaced as 
effective. With a few successful chemical conditions established, there had to be 
addressed the enormous instability of oripavine-iron-carbonyl complex 70. 
During many attempts to workup the reaction mixture, complete decomposition 
would ensue upon reaching pH = 8. Decomposition was characterized by visible 
turning of the orange solution to a suspension of black ash or rag within seconds 
of the aqueous phase becoming alkaline. Eventually, with more careful 
measurements of the volumes and concentrations used, a calculated pH = 7.4 
gave optimal product partitioning into the organic phase [CHCl3/iPrOH (9:1)] with 
minimal decomposition of the iron-complexed amino acid morphinan.  
 Once a viable workup procedure for oripavine iron complex 70 had been 
developed, many more reaction conditions were tried to decomplex the iron 
tricarbonyl without oxidation of the phenolic A ring or acidic hydrolysis of the C 
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ring. This step proved to be most difficult, only a few occasions did recognizable 
oripavine emerge.  
 
Entry Conditions Result 
1 TMANO, MeOH decomp. 
2 CAN, MeOH50 decomp. 
3 CuCl2, EtOH decomp. 
4 FeCl3, EtOH decomp. 
5 UV, MeCN51 35% 
 
Table 2. Iron tricarbonyl decomplexation of oripavine. 
 
 
Unfortunately, the deprotection step was poor in yield and sensitive to reaction 
time, challenging the consumption of starting material, yet not leading to 
decomposition of the newly formed product. Given the rather disappointing 
results with the decomplexation protocols we turned to Kirby’s method of 
reversible Diels-Alder reaction as means of protection of the diene system in 
thebaine. 
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3.1.2 C-Ring protection as thiopyran 
 Thioaldehyde cycloaddition is still a relatively unexplored method for 
heterocyclic synthesis. The reactive diene of thebaine was reacted with the 
thioaldehyde derived from 71 leading to the dihydrothiopyran adducts shown in 
Scheme 12.  
 
Scheme 12. Thebaine to oripavine through a thioformyl protection 
strategy. a) NEt3, CaCl2·2H2O, [MeOH/C6H6 (1:1)], 72:73:74 1:4.2:3.2, 80%. 
 
 
The [2.2.2]bicyclic products were separated by column chromatography for 
individual characterization. The minor compound 72 formed appropriate crystals 
for X-ray diffraction studies, Figure 10. This regioisomer was never carried to the 
next sequence of transformational studies. 
24 
 
 
Figure 10. Labeled representation of one of the two crystallographically-
independent molecules of 72 in the unit cell. 
 
Each of the two major isolated dihydrothiopyran adducts 73/74 (epimeric) were 
subjected to identical 3-O-demethyation conditions for easy monitoring and 
characterization of products in the event of success.  
 
Entry Conditions Result 
1 BBr3, CH2Cl2, 0 °C 85% 
2 BF3·SMe2, CH2Cl2 0 °C 50% 
3 MeSO3H, methionine, 50 °C 51% 
4 9-I-9-BBN, CH2Cl2, 20 °C 72% 
5 Dodecanethiol, NaOMe, DMF, reflux decomp. 
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6 NbCl5, CH2Cl2, rt decomp. 
7 NbCl5, DCE, reflux decomp. 
8 TMSI, MeCN, reflux no rxn 
9 TMSCl, NaI, MeCN, reflux no rxn 
10 CeCl3·7H2O, NaI, MeCN, reflux no rxn 
 
 Table 3. 3-O-Demethylation studies of dihydrothiopyrans. 
 
Once O-demethylation conditions were established, (interestingly, their 
attainment coincided with the successful deprotection of the iron carbonyl 
complexe), the final deprotection was accomplished in a relatively easy chemical 
sequence. The published procedures by Kirby18–20 indicated the reversibility of 
the thioaldehyde cycloaddition, which was exploited below, Scheme 13, in two 
different ways. 
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Scheme 13. Dihydrothiopyran cycloreversion to produce oripavine. 
a) 2,3-Dimethylbutadiene (20 eq.), DMSO, 75 °C, sealed tube, 65%; b) 
mCPBA, CH2Cl2, rt; c) EtOH, reflux, 78% (2 steps). 
 
Thermal cycloreversion and competitive capture of the thioaldehyde by a diene 
was first attempted, though it proved to be not ideal ase the use of an 
emulsifying solvent and sealed tube conditions complicated handling. The 
conversion to oripavine was never observed to reach completion. To obviate this 
problematic equilibrium of competitive Diels-Alder reactions and the possibility 
of polymerization of the thioaldehyde scavenger, the dihydrothiopyran 75 or 76, 
was oxidized to the sulfoxide 77, which was then heated to extrude a 
thioaldehyde-S-oxide that was easily captured irreversibly by the solvent. This 
condition led to greater yields and simpler product isolation, though they did 
27 
 
require the use of exactly one molar equivalent of mCPBA, because of concerns 
with possible over oxidation at N-17. 
 This newly developed sequence of transformations was again applied to 
thebaine with the aim of yield optimization. Through three telescoped steps with 
no isolation isomeric intermediates, oripavine was prepared in an overall  yield 
of 44% from thebaine with one chromatographic purification.52  
 
3.2 Chemoenzymatic synthesis of a flacourtia aglycone methyl ester 
 The aglycone was seen though pattern recognition as an entity that could 
be derived from the chemoenzymatic oxidation of benzoic acid. The aglycone 
fragment,36–39 bearing a strange array of oxidation, teetering on the edge of 
aromatization, had never before been synthesized, so its pursuit as a target 
seemed worthy.  
 
Scheme 14. Hydrolysis of flacourtoside. a) Ba(OH)2·8H2O, H2O, reflux.37 
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 Through a process first described by Myers53 and Banwell,54 and further 
refined by Dr. Adams of the Hudlicky group55, the β-lactone 81 was reliably 
prepared, albeit in persistently low yields. From the known vinyl epoxide 82, a 
straight forward set of oxidations was seen as a means to arrive at the desired 
aglycone 79, Scheme 15. By selective opening of the vinyl epoxide with water  at 
the allylic position (without acetonide or methyl ester loss),56–59 the allylic 
alcohol of 83 could then by oxidized using the historically selective MnO2.  
3.3 Attempted synthesis of flacourtia aglycone 79. 
 
Scheme 15. Attempt one at synthesizing the flacourtia fragment. 
a) TFA, 2,2-DMP, 0 °C, 84%; b) Br2, NaHCO3, CH2Cl2, H2O, 0 °C, 45%; or 
NBS, CH2Cl2, PhMe, 20 °C, 85%; c) NaOMe, MeOH, 0 °C, 79%; d) 5% 
Bi(OTf)3, H2O, MeCN, 20 °C, 72%; e) MnO2, EtOAc, 20 °C, 60%. 
 
The consistent appearance of the over oxidation product 84/85 forced the 
exploration of more exotic and “selective” allylic alcohol oxidation conditions, as 
shown in Table 4. 
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 DDQ is an effective oxidant of cyclic systems resembling the same allylic 
1,2-diol present in 83. However, while performing the reaction, no progress was 
seen at room temperature, and so other reagents and conditions were explored. 
[A solution for this oxidation was eventually found by simply heating the reaction 
mixture with DDQ. In hindsight, this may have been the best course of action from the 
start; suffice it to say that the hunt for these successful conditions took almost two 
months of effort]. Venturing onward to riskier oxidations, IBX in DMSO was tried, 
though these conditions resulted in full decomposition to chromatographically 
inert material. The propensity of 1,2-diol oxidation by C-C bond cleavage is 
documented, especially on strained cyclic systems.60 
 The use of catalytic N-oxyl radicals as selective oxidizing agents has 
recently grown in popularity, though when applied to this case, the use of PIFA 
was presumed to have led to the same oxidative cleavage of 83 as observed by 
IBX. 
 
Entry Conditions Result 
1 DDQ, EtOAc, rt61 no rxn 
2 IBX, DMSO, rt decomp. 
3 PIFA, K2CO3, AZADO, MeCN, CH2Cl2, rt62 decomp. 
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4 4-MeO-C6H4-B(OH)2, DBI, H2O, 0 °C, (dark)63 no rxn 
5 IBX, [bmim]Cl, H2O, rt, 3h64 65% 
 
Table 4. Selective oxidation of an allylic 1,2-diol. 
 
A recently published procedure reported the use of catalytic p-anisole boronic 
acid and stoichiometric DBI in the dark, appeared- at least on paper-to be 
promising, though after conducting the reaction twice, no progress was 
observed. Finally, in a desperate fancy, IBX was revisited, but this time in an ionic 
liquid, 1-butyl-3-methylimidazolium chloride, [bmim]Cl. With some surprise, the 
acyloin 86 was isolated as a white solid after careful removal of the ionic liquid. 
 With all atoms in the correct oxidation state, all that remained was the 
epimerization of the ketol 86 and deprotection. While it was speculated at the 
beginning that epimerization should ensue spontaneously to the natural 
diastereomer 79, no such isomerism was observed. Two different methods were 
employed to effect this stereochemical inversion, Scheme 16, but none 
succeeded. Mitsunobu reaction performed by the preformation of the 
phosphonium imide, cannulation to the ketol 86, followed by addition of p-
nitrobenzoic acid was also met with no success.  
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Scheme 16. Attempted α-Hydroxy-ketone inversion.  
a) DEAD, nBu3P, THF, 4-NO2-BzOH, 0 °C to rt; b) TMSCl, NEt3, THF, 0 °C, 
then DBU.  
 
 
 Another attempt began with silyl ether formation and subsequent 
enolization with expected equilibration to the natural (more stable) 
diastereomer; this, however, led to an unforeseen ejection of the tertiary 
acetonide bond, driven by aromatization. The resulting 2,3,6-trihydroxy methyl 
benzoate was oxidized by atmospheric oxygen to the p-quinone 88. The mass 
spectrum of this compound very closely resembled the fragmentation pattern of 
2,3,4-trihydroxy methyl benzoate, though 13C-NMR presented contradictory 
chemical shift data. The exact identity of this unexpected product remains 
unconfirmed.  
 Accepting the lack of success to force the isomerization, we turned to 
acetonide removal through acidic solvolysis to provide the α,β,γ-trihydroxy 
cyclohexenone. Unfortunately, such processes only led to decomposition. This 
transformation, though mundane, was unsuccessful and led only to complete 
loss of reaction contents, Table 5. 
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Entry Conditions Result 
1 PPTS, H2O, THF no rxn 
2 NaHSO4·SiO2, CH2Cl2, iPrOH no rxn 
3 FeCl3·SiO2, CHCl3 (Kim’s Reagent) no rxn 
4 TFA, H2O, MeCN, 0 °C, 45 min decomp. 
 
Table 5. Acetonide removal.  
 
 
It became quite clear that a better method must be devised to achieve the 
synthetic goal.  
 
3.3.1 Donohoe Dihydroxylation Approach 
 Reevaluation of the starting material with respect to the target and 
recent knowledge of a specific methodology empowered a new pathway. 
Selective protection of the secondary allylic alcohol provided 90. An H-bond-
directed osmium dihydroxylation65,66 led to triol 91. The reminiscent allylic 
alcohol was yet again found to be inexplicably unreactive to oxidizing conditions.  
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Scheme 17. Attempt two at synthesizing the flacourtia fragment. 
a) 4-Br-BzCl, TMEDA, CH2Cl2, –78 °C, 84%; b) OsO4, TMEDA, CH2Cl2, –78 
°C, 93%; c) DDQ, dioxane, 70 °C, 82%; d) LiOH, THF, H2O, decomp. 
 
The previously successful use of IBX in [bmim]Cl led to slow conversions and 
there was great difficulty in recovering the triol 91 from the ionic liquid reaction 
medium.  
 
Entry Conditions Result 
1 IBX, [bmim]Cl, H2O, rt, 2 days trace 
2 cat. DDQ, Mn(OAc)3·2H2O, CH2Cl2, rt, 2 days67 trace 
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3 cat. DDQ, NaNO2, O2, AcOH, DMC, rt, 2 days67 trace 
4 DDQ, dioxane, 70 °C, 6 days 80% 
 
Table 6. Selective allylic oxidation. 
 
 
Eventually, an effective method for oxidation of allylic alcohols in cyclic systems 
revealed itself through the use of DDQ. The elevated temperature was necessary 
to consume starting material in a reasonable amount of time.  Later, TLC analysis 
of saved samples showed that all the oxidation systems previously attempted 
worked, albeit at very slow rates. 
 With the ultimate intermediate prepared, the hydrolysis of the halo 
benzoate and methyl ester was done in sequence to avoid possible 
decarboxylation. The attempted hydrolysis using LiOH led to p-bromobenzoic 
acid as the only recognizable product. This additional frustration led to the last 
attempt at the synthesis through the use of a silyl protecting group. 
 Beginning again with the methyl ester ipso-diol 55, the secondary alcohol 
was transformed to the silyl ether 93. Donohoe dihydroxylation led in moderate 
yield to triol 94, which was cleanly oxidized to the ketol 95. Careful cleavage of 
the silyl ether provided the penultimate material 96. Saponification with barium 
hydroxide was executed according to the isolation article.37 With some suspicion 
of the procedure’s excessive force, compound 96 was dissolved in water and 
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stirred at room temperature for 2 h. TLC indicated no starting material, yet a 
yellow baseline spot upon KMnO4 staining.  
 
Scheme 18. Final attempt at the flacourtia fragment. 
a) TBSCl, imidazole, CH2Cl2, DMF, rt; b) OsO4, TMEDA, CH2Cl2, –78 °C; c) 
DDQ, dioxane, 85 °C; d) AcOH, TBAF, MeOH, 25 °C; e) Ba(OH)2·8H2O, H2O, 
100 °C. 
 
These synthetic sequences illustrate the importance of general methodological 
knowledge and the proper selection of protecting groups as these are needed.  
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4. CONCLUSION & FUTURE WORK 
 Organic synthesis continues to be a science learnt through empiricism, 
and rarely proceeds as idealistically predicted. Thebaine was transformed 
into oripavine through the use of iron(0) complexation or thioaldehyde 
cycloaddition as a means of cyclohexadienyl-ether protection. While not 
grabbing the attention of industrial innovators in semisynthetic opiate 
production, this work contributes to the niche of morphinans and diene 
protection strategies. Future work in this area includes the N-demethylation 
of thebaine and/or oripavine without the use of cyanogen bromide or 
chloroformates, as the product, oripavidine (nororipavine) constitutes the 
progenitor of all morphinan scaffolds of highest therapeutic value. 
 The ipso diol continues to show utility as a valuable chiron for the 
enantioselective synthesis of complex natural products. The diene-diol was 
used as a starting material to synthesize the strangely oxidized 
cyclohexenone aglycone belonging to the phenolglycosidic flacourtoside 
series. Initial use of the known vinyl epoxide led to a dead end and the 
approach was reevaluated to have the correct stereochemistry delivered 
through a Donohoe dihydroxylation. After experimentation with protection 
strategies and highly selective oxidizing reagents, strong bases and strong 
acids were more than capable of spurring substrate aromatization or 
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decomposition. The future is open to new targets derived from the unique 
ipso diol, as organic chemistry becomes ever more selective and clever. 
Academic organic synthesis strives, and continues to stand for the purpose of 
furthering the knowledge of carbon-based molecular transformations for the 
ultimate goal of harnessing Nature’s living architecture for the good of 
humankind.  
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5. EXPERIMENTAL 
5.1 General Experimental Details 
All non-aqueous reactions were conducted in an argon atmosphere using 
standard Schlenk techniques for the exclusion of moisture and air. All solvents 
were distilled unless otherwise noted. Analytical thin layer chromatography was 
performed on EMD Silica Gel 60 Å 250 μm plates with F-254 indicator. Column 
chromatography was performed using Silicycle SiliaFlash P60 (230-400 mesh). 
Melting points were recorded on a Hoover Unimelt apparatus and are 
uncorrected. Optical rotations were measured on a Mandel Rudolph Research 
Analytical Automatic Polarimeter at 589 nm with a cell length of 50 mm. IR 
spectra were obtained on a Bruker ATR FT-IR Spectrometer. 1H and 13C spectra 
were recorded on a 300 MHz, 400 MHz, and 600 MHz Bruker spectrometer. All 
chemical shifts are referenced to TMS or residual non-deuterated solvent. Data 
for proton spectra are reported as follows: chemical shift (multiplicity [singlet (s), 
doublet (d), triplet (t), quartet (q) and multiplet (m)], coupling constants [Hz], 
integration). Carbon spectra were recorded with proton decoupling and the 
chemical shifts are reported in ppm (C) relative to TMS. Mass spectra and high 
resolution mass spectra were performed by the analytical division at Brock 
University. Combustion analyses were performed by Atlantic Microlabs, Atlanta, 
GA, USA. 
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5.2 Detailed Experimental Procedures 
Sodium S-(cyanomethyl) sulfothioate, Bunte salt (71). 
 
Prepared according to a published protocol.19 A mixture of Na2S2O3·5H2O (9.97 g, 
63 mmol), chloroacetonitrile (5 g, 66 mmol), in [H2O/EtOH (1:1)] (40 mL) was 
heated at 80 °C for 1 h, then left at room temperature for 18 h. The mixture was 
cooled to 0 °C and then filtered, and rinsed with EtOH. The product was 
recrystallized from hot EtOH and dried under reduced pressure to yield (7.06 g, 
64%). mp 90-92 °C (EtOH); IR (neat) ν 3623, 3448, 2966, 2260, 1637, 1209, 1034 
cm–1. 
 
Thioaldehyde adduct isomers, 72, 73, and 74. 
Thebaine (930 mg, 3 mmol), CaCl2·2H2O (620 mg, 4.2 mmol), and 71 (735 mg, 4.2 
mmol) were dispersed in C6H6 (7 mL) and MeOH (7 mL) and stirred vigorously 
(large stir bar is necessary). Triethylamine (420 mg, 4.2 mmol) was added drop-
wise. After stirring at room temperature for 8 h, the reaction mixture was diluted 
with EtOAc (20 mL), and then centrifuged for 20 min at 7000 rpm. The 
supernatant was concentrated under reduced pressure and the crude residue 
was purified by column chromatography [hexane/EtOAc (2:1)]. Each isomer was 
crystallized from MeOH, total yield (910 mg, 80%).  
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(–)-(4R,4aS,7R,7aR,12bR,15R)-7,9-Dimethoxy-3-methyl-1,2,3,4,7,7a-hexahydro-
7,4a-(epithiomethano)-4,12-methanobenzofuro[3,2-e]isoquinoline-15-
carbonitrile (72). 
 
(110 mg, 12%); Rf = 0.73 [hexane/EtOAc (1:1)]; mp 184-185 °C (MeOH); [α]
20
𝐷
 = –
319.1° (c = 1.0, CHCl3); IR (neat) ν 2915, 2841, 2797, 2232, 1442, 1050, 869, 817, 
795, 592 cm–1; 1H NMR (600 MHz, CDCl3) δ 6.66 (d, J = 8.2 Hz, 1H), 6.59 (d, J = 8.2 
Hz, 1H), 6.39 (dd, J = 9.1, 1.3 Hz, 1H), 5.66 (d, J = 9.1 Hz, 1H), 5.38 (s, 1H), 4.92 (s, 
1H), 3.80 (s, 3H), 3.62 (s, 3H), 3.54 (d, J = 6.6 Hz, 1H), 3.31 (d, J = 18.6 Hz, 1H), 
2.55 (dd, J = 18.6, 6.6 Hz, 2H), 2.46-2.38 (m, 4H), 2.01-1.93 (m, 1H), 1.90 (dd, J = 
13.6, 2.9 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 146.8, 142.2, 133.2, 131.5, 130.9, 
126.9, 119.6, 119.1, 113.7, 92.3, 89.9, 59.1, 56.4, 53.9, 47.6, 45.0, 43.5, 36.1, 
33.8, 22.8; MS (EI+, m/z (rel.%)) 382 (93), 311 (50), 325 (23), 296 (25), 267 (22), 
255 (35), 230 (55), 58 (100); Anal. Calcd. for C21H22N2O3S: 382.14, found 382.13. 
CCDC #988979. 
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(–)-(4R,4aS,7S,7aR,12bS,14S)-7,9-Dimethoxy-3-methyl-1,2,3,4,7,7a-hexahydro-
4a,7-(epithiomethano)-4,12-methanobenzofuro[3,2-e]isoquinoline-14-
carbonitrile (73). 
 
(450 mg, 50%); Rf = 0.58 [hexane/EtOAc (1:1)]; mp 145-150 °C; [α]
20
𝐷
 = –218.2° (c 
= 1.0, CHCl3); IR (neat) ν 2935, 2836, 2792, 2234, 1499, 1279, 1107, 1021, 906, 
793 cm–1; 1H NMR (600 MHz, CDCl3) δ 6.65 (d, J = 8.1 Hz, 1H), 6.56 (d, J = 8.1 Hz, 
1H), 5.91 (q, J = 9.1 Hz, 2H), 5.00 (s, 1H), 3.83 (s, 3H), 3.77 (s, 1H), 3.67 (s, 3H), 
3.39 (d, J = 6.6 Hz, 1H), 3.27 (dd, J = 18.3, 10.6 Hz, 1H), 2.93 (td, J = 12.7, 5.5 Hz, 
1H), 2.68 (dd, J = 12.2, 5.3 Hz, 1H), 2.53-2.44 (m, 2H), 2.40 (s, 3H), 1.89 (dd, J = 
13.1, 2.5 Hz, 1H) the proton NMR contains an impurity, likely compound 72; 13C 
NMR (151 MHz, CDCl3) δ 147.0, 142.5, 138.0, 133.2, 126.6, 124.6, 119.9, 117.4, 
114.6, 91.4, 79.9, 60.0, 56.9, 53.9, 52.9, 50.5, 45.8, 43.4, 35.2, 32.7, 23.2; MS 
(EI+, m/z (rel.%)): 382 (7), 311 (95), 297 (50), 255 (22); HRMS (ESI) Anal. Calcd. 
for C21H22N2O3S: 382.1351, found 382.1351.  
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(+)-(4R,4aS,7S,7aR,12bS,14R)-7,9-Dimethoxy-3-methyl-1,2,3,4,7,7a-hexahydro-
4a,7-(epithiomethano)-4,12-methanobenzofuro[3,2-e]isoquinoline-14-
carbonitrile (74). 
 
(350 mg, 38%): Rf = 0.50 [hexane/EtOAc (1:1)]; mp 164-165 °C; [α]
20
𝐷
 = +5.9° (c = 
1.0, CHCl3); IR (neat) ν 2948, 2802, 2235, 1500, 1284, 1108, 1019, 894, 760 cm–1; 
1H NMR (600 MHz, CDCl3) δ 6.66 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.00 
(d, J = 8.8 Hz, 1H), 5.95 (d, J = 9.0 Hz, 1H), 4.52 (s, 1H), 4.08 (s, 1H), 3.83 (s, 3H), 
3.68 (s, 3H), 3.47 (d, J = 6.5 Hz, 1H), 3.26 (d, J = 18.5 Hz, 1H), 2.71 (td, J = 12.6, 5.5 
Hz, 1H), 2.61 (dd, J = 12.2, 5.3 Hz, 1H), 2.54 (dd, J = 18.5, 6.6 Hz, 1H), 2.47-2.40 
(m, 1H), 2.39 (s, 3H), 1.81 (dd, J = 12.8, 2.7 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 
146.5, 142.5, 136.4, 133.1, 126.4, 126.4, 120.2, 117.8, 114.1, 90.8, 80.2, 77.3, 
77.0, 76.8, 60.1, 56.6, 53.1, 52.5, 50.7, 45.6, 43.3, 35.7, 32.9, 23.2; MS (EI+, m/z 
(rel.%)): 382 (7), 311 (95), 296 (50), 255 (22); HRMS (ESI) Anal. Calcd. for 
C21H22N2O3S; 382.1351, found 382.1455. 
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O-Demethylated Thioaldehyde adduct isomers 73 and 74 
Method A: To a solution of 73 and/or 74 (200 mg, 0.52 mmol) in CH2Cl2 (10 mL) 
was slowly added BBr3 (0.780 g, 3.12 mmol) at 0 °C. Reaction was stirred for 20 
min at 0 °C and then removed from the ice bath and stirred for another 15 min. 
The reaction mixture was poured into ice water (20 mL) and acidity was slowly 
adjusted to pH = 8 with 15% aqueous NaOH. Mixture was extracted with CH2Cl2 
(3 x 10 mL). Combined organic phases were concentrated under reduced 
pressure and purified by column chromatography [hexane/EtOAC (1:1)] yielding 
75 and/or 76 (162 mg, 85%).  
Method B: To a solution of 73 (150 mg, 0.4 mmol) in dry CH2Cl2 (15 mL) was 
slowly added BF3·SMe2 complex (0.25 mL, 2.36 mmol) at 0 °C. Reaction was 
stirred for 4 h at 0 °C and then 2 h at room temperature. The reaction was then 
decanted into ice-water (20 mL) and the acidity was slowly adjusted to pH = 8 
with 15% aqueous NaOH. The aqueous layer was extracted with CH2Cl2 (3 x 10 
mL). The organic layers were combined and then washed with brine and dried 
over Na2SO4, concentrated under reduced pressure, then purified by column 
chromatography [hexane/EtOAc 1:1)] to yield 75 (74 mg, 50%).  
Method C: To a solution of 73 (170 mg, 0.395 mmol) in dry MeSO3H (1.15 mL, 
11.8 mmol) was slowly added rac-methionine (90 mg, 0.594 mmol). The orange 
solution was then heated to 50 °C and left to stir for 8 h. The reaction was 
44 
 
monitored by HPLC. The reaction was then decanted into ice water (20 mL) and 
the acidity was slowly adjusted to pH = 8 with 15% aqueous NaOH solution. The 
aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The organic layers were 
combined and then washed with brine and dried over Na2SO4, concentrated 
under reduced pressure and the product purified by column chromatography 
[hexane/EtOAc (1:1)] to yield 75 (73 mg, 51%).  
Method D: To a solution of 73 and/or 74 (110 mg, 0.287 mmol) in dry CH2Cl2 (5 
mL) was slowly added 9-I-9-BBN (0.86 mL, 1M in hexanes) at room temperature. 
After 4 h, the reaction mixture was decanted into ice-water (20 mL) and the 
acidity was slowly adjusted to pH = 8 with 15% aqueous NaOH. The aqueous 
layer was extracted with CH2Cl2 (3 x 10 mL). The organic layers were combined 
and then washed with brine and dried over Na2SO4, concentrated under reduced 
pressure, then purified by column chromatography [hexane/EtOAc (1:1)] to yield 
75 and/or 76 (80 mg, 72%).  
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(–)-(4R,4aS,7S,7aR,12bS,14S)-9-Hydroxy-7-methoxy-3-methyl-1,2,3,4,7,7a-
hexahydro-4a,7-(epithiomethano)-4,12-methanobenzofuro[3,2-e]isoquinoline-
14-carbonitrile (75). 
 
75: Rf = 0.35 [hexane/EtOAc (1:1)]; mp 145 °C (EtOAc); [α]
20
𝐷
 = –199.2° (c = 0.25, 
MeOH); IR (neat) ν 3189, 2936, 2803, 2235, 2069, 1455, 1154, 1102, 1028, 943, 
905, 757 cm–1; 1H NMR (600 MHz, MeOH-d4) δ 6.53 (d, J = 8.1 Hz, 1H), 6.48 (d, J = 
8.1 Hz, 1H), 6.02-5.95 (m, 2H), 4.83 (s, 1H), 4.15 (s, 1H), 3.62 (s, 3H), 3.42 (d, J = 
6.6 Hz, 1H), 3.26 (d, J = 18.5 Hz, 1H), 2.87 (td, J = 12.7, 5.5 Hz, 1H), 2.64 (dd, J = 
12.2, 5.2 Hz, 1H), 2.56 (dd, J = 18.5, 6.7 Hz, 1H), 2.46 (td, J = 12.3, 3.7 Hz, 1H), 
2.37 (s, 3H), 1.81 (dd, J = 13.0, 2.8 Hz, 1H); 13C NMR (151 MHz, MeOH-d4) δ 146.9, 
140.2, 139.5, 134.1, 126.8, 124.4, 121.2, 118.9, 118.5, 92.7, 81.2, 61.2, 54.0, 
53.7, 51. 6, 49.9, 46.9, 43.5, 35.4, 33.7, 24.0; MS (EI+, m/z (rel.%)): 368 (10), 297 
(40), 241 (15), 184 (40); HRMS (ESI) Anal. Calcd. for C20H20N2O3S: 368.12, found 
368.11.  
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(–)-(4R,4aS,7S,7aR,12bS,14R)-9-Hydroxy-7-methoxy-3-methyl-1,2,3,4,7,7a-
hexahydro-4a,7-(epithiomethano)-4,12-methanobenzofuro[3,2-e]isoquinoline-
14-carbonitrile (76). 
 
76: Rf = 0.23 [hexane/EtOAc (1:1)]; mp 170-174 °C (EtOAc); [α]
20
𝐷
 = –1.16° (c = 0.5, 
MeOH); IR (neat) ν 3509, 3358, 2926, 2803, 2241, 1638, 1497, 1112, 1030, 891, 
761 cm–1; 1H NMR (600 MHz, DMSO-d6) δ 6.49 (d, J = 8.0 Hz, 1H), 6.43 (d, J = 8.0 
Hz, 1H), 6.03 (d, J = 8.9 Hz, 1H), 5.74 (d, J = 8.7 Hz, 1H), 4.94 (s, 1H), 4.73 (s, 1H), 
3.51 (s, 3H), 3.43 (d, J = 6.4 Hz, 1H), 3.10 (d, J = 18.4 Hz, 1H), 2.65 (td, J = 12.7, 5.4 
Hz, 1H), 2.57-2.45 (m, 8H), 2.27 (s, 3H), 2.26-2.20 (m, 1H), 1.63 (dd, J = 12.9, 2.6 
Hz, 1H); 13C NMR (151 MHz, DMSO-d6) δ 145.2, 138.9, 136.5, 132.9, 126.8, 124.8, 
119.9, 118.7, 117.1, 87.1, 79.9, 59.2, 52.5, 51.4, 50.1, 45.2, 42.8, 33.6, 32.2, 22.5; 
MS (EI+, m/z (rel.%)): 362 (10), 297 (20), 78 (90), 63 (100); HRMS (ESI) Anal. 
Calcd. for C20H20N2O3S: 368.1195, found 368.1195. 
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(–)-Oripavine 2. 
 
Method E: To a solution of 75 (400 mg, 1.09 mmol) in DMSO (1.5 mL) was added 
2,6-di-tert-butyl-4-methylphenol (BHT) (21 mg, 0.109 mmol) and 2,3-
dimethylbutadiene (2.5 mL, 22.1 mmol), which was then charged to a sealed 
tube. The reaction was stirred vigorously for 24 h at 75 °C. The 2,3-
dimethylbutadiene was removed by under reduced pressure and the residue 
dissolved CHCl3 (20 mL). The organic solution was washed with H2O (5 mL), then 
concentrated under reduced pressure. The residue was purified by column 
chromatography [CH2Cl2/MeOH (9:1)] to yield oripavine 2 (210 mg, 65%). NMR 
spectra, Rf, and mp, were in agreement with previously published data.68 
Method F: To a solution of 76 (66 mg, 0.18 mmol) in CH2Cl2 (2 mL) was added 
mCPBA 77% (40 mg, 0.18 mmol) at room temperature for 18 h. The solvent was 
evaporated under reduced pressure and the solid was then dissolved in EtOH (20 
mL) and then heated to reflux for 2.5 h. The solvent was evaporated under 
reduced pressure and the crude residue purified by column chromatography 
[CHCl3/MeOH (4:1)] to yield oripavine 2 (42 mg, 78%).  
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2: Rf = 0.25 [CHCl3/MeOH (4:1)]; [α]
20
𝐷
 = –215.2° (c = 3.5, CHCl3), [lit.68 [α]
20
𝐷
 = –
216.9° (c = 3.44, CHCl3)]; mp 200-201 °C (MeOH), lit.[68] mp 201-203 °C 
(EtOH); 1H NMR (300 MHz, CDCl3) δ 6.65 (d, J = 8.1 Hz, 1 H), 6.55 (d, J = 8.1 Hz, 1 
H), 5.57 (d, J = 6.4 Hz, 1 H), 5.30 (s, 1 H), 5.07 (d, J = 6.4 Hz, 1 H), 3.82-3.50 (m, 
4 H), 3.31 (d, J = 18.0 Hz, 1 H), 2.87 (t, J = 11.2 Hz, 1 H), 2.79-2.58 (m, 2 H), 2.47 
(s, 3 H), 2.23 (td, J = 12.7, 5.2 Hz, 1 H), 1.74 (d, J = 12.2 Hz, 1 H). The NMR spectra 
matched previously published data. 
Direct conversion of thebaine to oripavine: 
Thebaine (250 mg, 0.8 mmol), CaCl2·2H2O (146 mg, 1.0 mmol), and 71 (175 mg, 
1.0 mmol), were dispersed in C6H6 (4.5 mL) and methanol (5.5 mL). A large 
stirring bar is necessary to prevent seizing. The mixture was stirred for 5 min, 
then NEt3 (0.14 mL, 1.0 mmol) was added drop-wise over 90 min at room 
temperature. Slow addition of base is necessary to prevent thioaldehyde 
polymerization. The off-white solution/suspension began to turn yellowish with 
more base added. The reaction mixture was stirred at 400 rpms for 18 h with no 
special exclusion of moisture or atmosphere. The reaction was diluted with 
EtOAc (15 mL), then filtered through a plug of sand and Celite. The organic 
solvents were then removed under reduced pressure, and the orange solid 
residue as a mixture of isomers 72, 73, and 74, was carried on to the next step 
without further purification.  
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The mixture of the isomeric adducts were dissolved in CH2Cl2 (10 mL) and cooled 
to 0 °C. BBr3 (0.77 mL, 8.0 mmol) was then added in a single portion. The 
transparent orange solution immediately turned an opaque brown. The reaction 
was allowed to progress for 20 min. The reaction was quenched by the addition 
of ice-cold water (1 mL), then slowly, ice-cold 10% NaOH solution (10 mL) was 
added. The slightly basic biphasic solution was then filtered through a short plug 
of sand and silica to remove boron and bromide byproducts. The reaction vessel 
was washed with [CHCl3/iPrOH (9:1)] (2 x 15 mL). The orange transparent filtrate 
was washed with brine (5 mL), dried over MgSO4, and then concentrated under 
reduced pressure to provide a mixture of 3-O-demethylated isomers (213 mg, 
72% for 2 steps). Note: the 3-O-demethylated compound arising from 72, was 
never characterized, merely observed by TLC. 
The mixture of dihydrothiopyran adducts 75 and 76 (200 mg, 0.54 mmol) of 
oripavine were dissolved in [iPrOH/DMSO (8:1)] (2.25 mL), then transferred to a 
sealed tube. 2,3-Dimethylbutadiene (1.8 mL, 16.2 mmol) was added under 
argon, then the tube was sealed and heated to 80 °C behind an explosion-proof 
shield for 20 h. The completion of the reaction was confirmed by TLC and HPLC-
MS, as oripavine appeared as the major product. The volatiles were removed 
under reduced pressure, then crude mixture was then purified by flash column 
chromatography [CHCl3/MeOH (4:1)] to provide oripavine 2 (105 mg, 65%, 44% 
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overall yield for three steps). NMR spectra, Rf, and mp, were in agreement with 
previously published data.68 
 
Sodium (–)-(1S,6R)-1,6-Dihydroxycyclohexa-2,4-dienecarboxylate (4). 
 
The whole-cell biotransformation of benzoic acid was performed based on a 
modified procedure established by Mihovilovic and co-workers.69 Lysogeny broth 
(LB)(II) medium (100 mL) was inoculated with a single colony of Ralstonia 
eutrophus B9 that was grown on LB(II) agar plates at 30 °C for two days. The 
inoculated medium was incubated at 30 °C on an orbital shaker at 185 RPM until 
OD256 = 4.8 (1:10 dilution; 24 h). The cellular suspension (80 mL) was used as a 
pre-culture and added to a 15 L Sartorius Biostat C bioreactor that contained 
Hutner’s Mineral Base (HMB) medium (8.4 L) at pH = 7.4, aerated with sterile air 
at 3 L min-1, agitation speed of 300 RPM, and D-fructose (50 mL of a 1.5 M 
aqueous solution) concentration of 0.009 M. The culture was grown until an 
OD256 = 2.8 (1:10) was achieved (20 h), and then induced with sodium benzoate 
(12 mL of a 1.5 M aqueous solution; 18 mmol) and D-fructose (53 mL of a 1.5 M 
aqueous solution; 80 mmol). After 6 h, consumption of benzoate was observed 
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by UV analysis (265 nm) and a repetitive feeding program was initiated at which 
15 min feeding of an aqueous solution of sodium benzoate (22 mL, 1.5 M; 1.5 
mL/min feed rate) and aqueous D-fructose (22 mL, 1.5 M; 1.5 mL/min feed rate) 
was performed every 3 h over the course of 4 d; a total of 170 g of sodium 
benzoate was fed. After the feeding regime was completed the broth was 
drained and separated from cell matter by centrifugation at 5 °C (10,000 RPM). 
The dark brown ferment broth was concentrated by rotary evaporation at 45 °C 
to provide the ipso diene diol carboxylate as the mixed potassium/sodium salt. 
NMR spectroscopy assay was used to establish a weight-weight percentage of 
the crude material with an internal standard (potassium benzoate). A total mass 
of 240 g of crude material was obtained and corresponded to 162 g of the salt of 
ipso diol 4 that could be stored at room temperature.  
HMB Media for 8 L Fermentation: 
KOH (3.2 g), nitriloacetic acid (1.6 g), MgSO4.7H2O (4.64 g), CaCl2.2H2O (536 mg), 
(NH4)2SO4 (8 g), (NH4)2MoO4.4H2O (1.6 mg), FeSO4.7H2O (8 mg), KH2PO4 (21.76 g), 
Na2HPO4 (25.84 g) diluted in 8 L of distilled water. 
Hutner’s Metal Solution (8 mL): H2SO4 (100 μL), EDTA (0.5 g), ZnSO4.7H2O (2.2 g), 
FeSO4.7H2O (1 g), CuCl (340 mg), Co(NO3)2.6H2O (50 mg), Na2B4O7·10H2O (36 mg) 
diluted in 100 mL of distilled water. 
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4: Rf = 0.20 [EtOAc/MeOH (4:1)]; mp 201-203 °C (H2O; decomposition); [α]
20
𝐷
 = –
97.3° (c = 1.0, H2O) [lit.22 [α]
20
𝐷
 = –123.8° (c = 1.78, H2O)]; IR (neat) ν 3392, 3243, 
3037, 2884, 1591, 1408, 1394, 1007, 783, 686 cm–1; 1H NMR (300 MHz, D2O) δ 
6.03 (dd, J = 9.5, 5.2 Hz, 1H), 5.93-5.81 (m, 1H), 5.71-5.64 (m, 2H), 4.77 (s, 1H); 
13C NMR (75 MHz, D2O) δ 180.7, 131.0, 127.1, 126.1, 132.2, 75.1, 71.4. 
 
Sodium (–)-(3aS,7aR)-2,2-Dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-
carboxylate (80). 
 
To a slurry of mixed potassium/sodium carboxylate 4 (68 g (101 g at 67% purity), 
0.367 mol) in 2,2-DMP (900 mL, 0.4 M) at 0 °C with vigorous stirring was added 
TFA (168 mL, 2.2 mol) drop-wise over several minutes while the internal 
temperature was monitored. The reaction mixture was warmed up to room 
temperature and stirred until the consumption of 4 was observed by TLC. The 
reaction mixture was filtered over a bed of diatomaceous earth and the filtrate 
was concentrated under reduced pressure to a dark brown oil. The crude 
mixture was dispersed in water (100 mL), and extracted with CH2Cl2 (2 x 300 mL). 
The organic phases were then extracted with a saturated aqueous NaHCO3 
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solution (3 x 500 mL) and then concentrated to dryness under reduced pressure. 
The inorganic-salt-contaminated carboxylate was then dissolved in MeOH and 
the heterogeneous mixture was filtered. The filtrate was concentrated under 
reduced pressure to yield an off-white solid (55 g, 0.3 mol, 81% yield) of 
acetonide 80.  
80: Rf = 0.9 [EtOAc/MeOH (4:1)]; mp 87-91°C (MeOH) [no known literature 
value]; [α]20
𝐷
 = –218.2° (c = 1.0, MeOH) [no known literature value]; IR (neat) ν 
3434, 2988, 1680, 1603, 1386, 1207, 1133, 1029, 802, 722 cm–1; 1H NMR (300 
MHz, D2O) δ 6.13 (dd, J = 9.5, 5.6 Hz, 1H), 6.06 (dd, J = 9.6, 5.5 Hz, 1H), 5.92 (dd, J 
= 9.5, 4.3 Hz, 1H), 5.71 (dd, J = 9.9, 4.5 Hz, 1H), 4.80 (d, J = 4.2 Hz, 1H), 1.43 (s, 
3H), 1.33 (s, 3H).  
 
(+)-(3aR,5aS,6S,8aR)-6-Bromo-2,2-dimethyl-5a,6-
dihydrooxeto[3',2':1,6]benzo[1,2-d][1,3]dioxol-4(8aH)-one (81). 
 
Small scale: 
Acetonide 80 was dissolved in ice cold HCl 6 M (50 mL), then extracted with 
EtOAc (2 x 30 mL), dried over Na2SO4, then concentrated under reduced pressure 
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to provide the carboxylic acid (360 mg, 1.8 mmol). The acid was dissolved in 
[CH2Cl2/toluene (30:1)] (31 mL), then NBS (640 mg, 3.6 mmol) was added. The 
reaction was complete within 3 h at room temperature. The reaction mixture 
was concentrated under reduced pressure, then adsorbed onto silica. The 
material was then purified by flash column chromatography [hexane/EtOAc 
(4:1)]. The pure fraction contents crystallized in white spirals (167 mg, 1.5 mmol, 
85%). 
Large scale: 
Diene 80 (15 g, 76.5 mmol) was dissolved in H2O (100 mL). Saturated NaHCO3 
(100 mL) was then added, followed by CH2Cl2 (100 mL). This biphasic mixture was 
cooled to 0 °C and then Br2 (4 mL, 76.5 mmol) in CH2Cl2 (30 mL) was added drop-
wise over 45 min. The reaction was quenched by the addition of saturated 
NaHSO3 (50 mL) to ensure the disappearance of red color. The phases were 
separated and the CH2Cl2 layer collected. The aqueous layer was extracted with 
CH2Cl2 (2 x 150 mL). The combined organic layers were washed with brine, then 
dried over Na2SO4, concentrated under reduced pressure to provide a white 
precipitate. The residue was crystallized from CH2Cl2/Et2O at –20 °C (9.45 g, 
34.43 mmol, 45% yield), as white needles. 
81: Rf = 0.80 [hexane/EtOAc (2:1)]; mp 136-141 °C (CH2Cl2) [lit.53 mp 137-142 °C 
(not reported)]; [α]20
𝐷
 = +300.7° (c = 0.5, CHCl3); 1H NMR (600 MHz, CDCl3) δ 6.37 
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(dd, J = 10.0, 4.5 Hz, 1H), 6.23-6.03 (m, 1H), 4.92 (d, J = 4.4 Hz, 1H), 4.78 (d, J = 
3.5 Hz, 1H), 4.63 (t, J = 4.0 Hz, 1H), 1.55 (s, 3H), 1.44 (s, 3H); 13C NMR (151 MHz, 
CDCl3) δ 168.5, 134.0, 122.9, 112.9, 87.3, 78.2, 77.2, 77.0, 76.8, 73.2, 40.3, 27.3, 
26.2. 
 
(–)-(3aR,5aR,6aR,6bR)-Methyl 2,2-dimethyl-3a,5a,6a,6b-
tetrahydrooxireno[2',3':3,4]benzo[1,2-d][1,3]dioxole-6b-carboxylate (82). 
 
Anhydrous MeOH (80 mL) was charged to a flame-dried 250 mL round bottom 
flask, then cooled to 0 °C. Sodium metal (3 g, 0.132 mol) was then added 
portion-wise, a slight exotherm was observed (vigorous evolution of H2, be ready 
to vent). When no solid sodium pieces remained, the β-lactone 81 (28 g, 0.102 
mol) was added in a single portion. The reaction mixture was stirred at room 
temperature for 18 h. The reaction was quenched by the addition of saturated 
NH4Cl solution, MeOH was evaporated under reduced pressure, then extracted 
with EtOAc (5 x 20 mL). The organic extracts were washed with brine, dried over 
MgSO4, and then concentrated under reduced pressure to provide a reddish-
brown syrup weighing 25 g. The crude mass was adsorbed onto 50 g 10% 
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deactivated silica, then purified by suction chromatography to provide a 
yellowish white solid (18.2 g, 80.5 mmol, 79% yield). 
82: Rf = 0.35 [hexane/EtOAc (4:1)]; mp 60-61 °C (EtOAc) [lit.53 mp 55-59 °C 
(EtOAc)]; [α]20
𝐷
 = –103.4° (c = 1.0, CHCl3); IR (neat) ν 2994, 1741, 1374, 1249, 
1034, 853, 552 cm–1; 1H NMR (600 MHz, CDCl3) δ 6.14 (ddd, J = 10.1, 3.9, 1.7 Hz, 
1H), 5.98-5.92 (m, 1H), 5.05-4.91 (m, 1H), 3.89 (s, 3H), 3.69 (d, J = 3.6 Hz, 1H), 
3.43 (td, J = 3.8, 0.9 Hz, 1H), 1.41 (s, 3H), 1.39 (s, 3H); 13C NMR (151 MHz, CDCl3) 
δ 171.9, 133.0, 123.7, 113.2, 80.6, 77.4, 77.2, 77.0, 73.4, 53.4, 51.7, 47.3, 28.4, 
27.4. 
 
Tris(trifluoromethanesulfonate)bismuth(III); Bi(OTf)3 was prepared according to 
a published protocol.70 Bi2O3 (0.5 g, 1.07 mmol) was suspended in [EtOH/H2O 
(3:1)] (7.5 mL). TfOH (0.57 mL, 6.44 mmol) was added at once with stirring. The 
reaction medium was heated to <65 °C for 3 h. The white cloudy mixture was 
concentrated by lyophilization to provide a free-flowing white powder (1.3 g, 1.9 
mmol, 93% yield).  
IR (neat) ν 3360, 1641, 1221, 1182, 1032, 629, 518 cm–1. 
 
(+)-(3aS,4R,5S,7aR)-Methyl 4,5-dihydroxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxole-3a-carboxylate (83). 
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To the vinyl epoxide 82 (150 mg, 0.66 mmol) was added Bi(OTf)3 (44 mg, 0.066 
mmol), then [MeCN/H2O (4:1)] (1.5 mL). The reaction mixture was aged for 2 h at 
room temperature. TLC (visualized by CAM stain) indicated consumption of 
starting material, and was thus concentrated under reduced pressure to a yellow 
oil with solid bismuth salt suspension. The residue was then dispersed in EtOAc 
and filtered through a short plug of sand and diatomaceous earth. The filtrate 
was then concentrated under reduced pressure. The diol was then purified by 
column chromatography [hexanes/EtOAc (1:4)] to provide a sticky, viscous, 
colorless, clear oil, with an odor of fresh soil, which solidified upon standing over 
3 d (115 mg, 0.47 mmol, 72% yield). 
83: Rf = 0.55 (EtOAc); mp 81-84 °C (EtOAc); [α]
20
𝐷
 = +38.0 (c = 2.85, MeOH); IR 
(neat) ν 3451, 2989, 1729, 1380, 1209, 1037, 876 cm–1; 1H NMR (600 MHz, 
DMSO-d6) δ 5.77 (d, J = 10.3 Hz, 1H), 5.69 (dd, J = 10.2, 2.0 Hz, 1H), 5.52 (d, J = 
4.5 Hz, 1H), 5.08 (d, J = 6.1 Hz, 1H), 4.56 (s, 1H), 4.14 (s, 1H), 3.64 (s, 3H), 3.37 
(dd, J = 7.9, 4.6 Hz, 1H), 1.41 (s, 3H), 1.29 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 
171.4, 135.6, 122.0, 110.5, 85.6, 76.2, 75.1, 69.1, 52.0, 40.1, 40.0, 39.8, 39.7, 
39.7, 39.6, 39.4, 39.3, 27.9, 26.0, 25.1; MS (EI) m/z (%) 240 (20), 229 (55), 199 
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(100). Anal. Calcd for C11H16O6: C, 54.09; H, 6.60. Found C, 54.31; H, 6.62. The 
stereochemistry of the vicinal diol were established by COSY, HSQC, and NOESY. 
 
(3aR,7aR)-Methyl 4,4-Dihydroxy-2,2-dimethyl-5-oxo-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxole-3a-carboxylate (84/85). 
 
To the trans-diol 83, (80 mg, 0.328 mmol) was added MnO2 (570 mg, 6.55 mmol) 
and EtOAc (10 mL). The mixture was vigorously stirred under argon for 10 days. 
The product was purified by filtration through Celite and subsequent adsorption 
to silica, then by chromatography [hexane/EtOAc (1:1)] to provide a yellow oil 
(65 mg, 0.271 mmol, 83% yield).  
84/85: Rf = 0.65 [hexane/EtOAc (1:1)]; [α]
20
𝐷
 = a sample of high enough purity 
could not be attained; IR (neat) ν 3442, 2992, 1713, 1382, 1266, 1119, 1041 cm–
1; 1H NMR (600 MHz, Acetone-d6) δ 7.34 (dd, J = 10.5, 4.1 Hz, 1H), 6.94 (dt, J = 
29.3, 14.6 Hz, 2H), 6.66 (d, J = 10.5 Hz, 1H), 6.25 (t, J = 11.7 Hz, 2H), 5.73 (s, 2H), 
5.44 (d, J = 4.1 Hz, 1H), 5.32 (s, 1H), 5.10 (d, J = 3.6 Hz, 2H), 3.83 (s, 3H), 3.72 (s, 
5H), 1.51 (s, 3H), 1.50 (s, 5H), 1.47 (s, 3H), 1.41 (s, 5H); 13C NMR (151 MHz, 
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Acetone-d6) δ 192.5, 188.6, 181.7, 169.9, 167.3, 146.4, 143.5, 132.2, 126.6, 
114.5, 112.9, 90.5, 87.7, 86.6, 77.9, 75.2, 52.9, 51.7, 26.8, 26.5, 25.7, 25.1; MS 
(EI) m/z (%) 229 (15), 159 (30), 109 (37), 95 (100); The proton and carbon data 
correspond to the mixture of α-diketone and its hydrate. The compound could 
not be purified to give clean HRMS data, and therefore it was never sent out for 
combustion analysis.  
 
2-Iodoxybenzoic acid (IBX). 
 
Prepared according to a published protocol.71 A three-neck round bottom flask 
equipped with stir bar and condenser was charged with KBrO3 (5.5 g, 33 mmol) 
and aqueous H2SO4 (44 mL, 0.5 M). The vessel was heated to 60 °C, and when all 
solids were dissolved, o-iodobenzoic acid (5.5 g, 22 mmol) was added portion-
wise over about 30 min. The reaction mixture turned orange and bromine vapor 
was evolved though the condenser and trapped by bubbling through a solution 
of saturated aqueous Na2S2O3. After about 2.5 h, the reaction vessel was cooled 
by ice bath and then the solids were collected by filtration. The filter cake was 
washed with ice-cold water (30 mL), EtOH (2 x 5 mL), then again with ice-cold 
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water (30 mL). The sticky white solid was dried under reduced pressure, then 
stored at –20 °C (5.3 g, 20 mmol, 91% yield).  
 
1-Butyl-3-methyl-1H-imidazol-3-ium chloride ([bmim]Cl). 
 
Prepared according to a published protocol.72 A round bottom flask equipped 
with stir bar and condenser was charged with 1-methyl imidazole (9.7 mL, 121 
mmol), n-butyl chloride (14 mL, 134 mmol), and toluene (12 mL), then heated to 
reflux for 20 h. The reaction mixture concentrated under reduced pressure to 
provide a viscous, odorless, amber liquid (21.1 g, 120.8 mmol, 99% yield).  
[Bmim]Cl: IR (neat) ν 3377, 2985, 1566, 1462, 1168, 623 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 10.93 (d, J = 7.2 Hz, 1H), 7.39 (s, 1H), 7.29 (s, 1H), 4.31 (t, J = 7.4 Hz, 2H), 
4.12 (s, 3H), 1.94-1.83 (m, 2H), 1.44-1.31 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 
 
(+)-(3aS,4S,7aR)-Methyl 4-hydroxy-2,2-dimethyl-5-oxo-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxole-3a-carboxylate (86). 
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[Bmim]Cl (1.5 mL) and water (0.3 mL) were mixed at room temperature in a flask 
open to atmosphere. IBX (154 mg, 0.55 mmol) was added, which dissolved over 
about 5 min. The trans-diol 83 (131 mg, 0.537 mmol) was then added in one 
portion and stirred for 3 h at room temperature. When the reaction was 
complete, the product was extracted with EtOAc (5 x 3 mL). The product was 
purified by flash column chromatography, to provide 86 as a white solid (105 mg, 
0.433 mmol, 80%) 
86: Rf = 0.42 [hexane/EtOAc (1:1)]; [α]
20
𝐷
 = +2.4 (c = 0.8, CHCl3); mp 101-103 °C 
(EtOAc); IR (neat) ν 3664, 2978, 2889, 1385, 1259, 1154, 967, 876 cm–1; 1H NMR 
(600 MHz, DMSO-d6) δ 6.94 (dd, J = 10.2, 4.0 Hz, 1H), 6.20 (dd, J = 10.2, 0.7 Hz, 
1H), 6.02 (d, J = 4.9 Hz, 1H), 5.02 (dd, J = 4.1, 0.6 Hz, 1H), 4.26 (d, J = 4.8 Hz, 1H), 
3.66 (s, 3H), 1.49 (s, 3H), 1.40 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 195.5, 
169.7, 140.2, 128.9, 111.3, 85.9, 75.0, 73.4, 52.4, 27.4, 25.5; MS (EI) m/z (%) 220 
(5), 205 (27), 149 (8), 105 (27), 85 (65), 83 (100), 72 (100); Anal. Calcd for 
C11H14O6: C, 54.54; H, 5.83; Found C, 54.39; H, 5.67. 
 
Methyl 2-Hydroxy-3,6-dioxocyclohexa-1,4-dienecarboxylate (88). 
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The ketol 86 (30 mg, 0.124 mmol) was dissolved in THF (0.6 mL, 0.2 M), then 
TMSCl (17.2 μL, 0.136 mmol), and then slowly NEt3 (19 μL, 0.136 mmol). The 
reaction mixture went from transparent to cloudy and TLC [hexane/EtOAc (2:1)] 
indicated full conversion to the silyl ether. DBU (30.5 μL, 0.248 mmol) was added 
slowly. The reaction mixture quickly turned to a dark red and a black precipitate 
formed. After 2 min, saturated NaHCO3 (2 mL) was added, followed by EtOAc (4 
mL). The material was then purified by flash chromatography [hexane/EtOAc 
(2:1)] to give a white solid (20 mg, 0.1098 mmol, 88% yield). 
88: Rf = 0.55 [hexane/EtOAc (1:1)]; mp 135-137 °C (CHCl3); IR (neat) ν 3410, 1675, 
1459, 1320, 1161, 1123, 790 cm–1; 1H NMR (600 MHz, CDCl3) δ 7.09 (d, J = 8.9 Hz, 
1H), 6.45 (d, J = 8.8 Hz, 1H), 5.20 (s, 1H), 4.12 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
169.8, 152.9, 137.5, 122.2, 107.3, 99.9, 53.1, 29.7; MS (EI) m/z (%) 184 (45), 152 
(100), 124 (40), 96 (20), 69 (15). Spectroscopic evidence for this compound has 
been somewhat contradictory, and it remains unclear exactly what the oxidation 
state of the aromatic ring is. Because this compound was a dead-end product it 
was not submitted for combustion analysis. 
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1-Methyl-1-nitrosourea (MNU). 
 
Prepared according to a published protocol.73 Ice-cold methylamine 40% aq (130 
mL, 1.5 mol) was placed in a 1 L round bottom flask equipped with addition 
funnel. Concentrated HCl (155 mL, 12 M) was poured into water (200 mL) then 
added slowly over 30 min to the methylamine solution. Urea (300 g, 5 mol) was 
added over several minutes with warming to the reaction solution. With the 
addition complete, the mixture was heated to reflux for 2 h (~150 °C) then 
allowed to cool to room temperature. NaNO2 (114 g, 1.65 mol) was added 
directly to the reaction mixture and stirred until it was a viscous transparent 
yellow solution.  
To a 5 L 3-neck round bottom flask equipped with a mechanical stirrer was 
added ice (600 g) and H2SO4 (53.5 mL, 1 mol), which was then cooled to <0 °C by 
a brine-ice bath. To this mixture was slowly added the nitrite/methylurea 
solution over about 1 h by addition funnel, keeping the internal reaction mixture 
temperature <5 °C. The precipitate was then collected by filtration, and the cake 
was washed with ice-cold water (50 mL) and then dried in a vacuum desiccator. 
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The dried light yellowish/orange white solid (127 g, 1.5 mol) was stored at –20 
°C. Please consult the MSDS of MNU, it is a very strong carcinogen.  
 
(–)-(1S,6R)-Methyl 1,6-Dihydroxycyclohexa-2,4-dienecarboxylate (55). 
 
To a solution of ipso diol 4 (4.0 g, 25.6 mmol) in THF (32 mL, 0.8 M) at 0 °C was 
added diazomethane (excess) in Et2O drop-wise over 30 min.74 The reaction 
mixture was allowed to warm to room temperature. After warming to ambient 
temperature the reaction mixture was titrated with AcOH (bubbling cessation) 
and then concentrated under reduced pressure to provide an orange oil. The 
crude mass was purified by column chromatography to provide a white solid 
(3.26 g, 19.2 mmol, 75% yield). 
55: Rf = 0.23 [hexane/EtOAc (1:1)]; mp 59-60 °C (Et2O) [lit.29 mp 59-60 °C (Et2O)]; 
[α]20
𝐷
 = –94.2° (c = 1.0, CHCl3) [lit.29 [α]
20
𝐷
 = –96.696° (c = 1.0, CHCl3)]; 1H NMR 
(300 MHz, CDCl3) δ 6.08 (dd, J = 9.5, 5.1 Hz, 1H), 5.95-5.84 (m, 1H), 5.82-5.68 (m, 
2H), 4.79 (d, J = 5.1 Hz, 1H), 3.84 (s, 1H), 3.81 (s, 3H), 3.39-3.23 (m, 1H).  
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(–)-(1R,6S)-6-Hydroxy-6-(methoxycarbonyl)cyclohexa-2,4-dien-1-yl 4-
bromobenzoate (90). 
 
The diene-diol 55 (1.2 g, 7.06 mmol) was dissolved in CH2Cl2 (30 mL, 0.24 M), 
then TMEDA (1.05 mL, 7.06 mmol) was added. The mixture was cooled to –78 °C, 
then 4-bromo-benzoylchloride (1.56 g, 7.13 mmol) in CH2Cl2 (5 mL) was added 
drop-wise. After a few minutes the transparent yellow solution became white 
and opaque. The reaction was allowed to progress for an additional 3 h, then 
quenched by the addition of saturated NaHCO3 (10 mL). The organic layer was 
collected, and the aqueous was extracted an additional time with CH2Cl2 (30 mL). 
The combined organic layers were dried over Na2SO4. The concentrated residue 
was purified by column chromatography gradient elution [hexane/EtOAc (9:1 to 
4:1)] to provide clear oil (2.1 g, 5.93 mmol, 84% yield).  
90: Rf = 0.75 [hexane/EtOAc (1:1)]; [α]
20
𝐷
 = –112.1° (c = 0.5, CHCl3); IR (neat) ν 
3483, 2953, 1718, 1588, 1256 cm–1; 1H NMR (300 MHz, CDCl3) 1H NMR (300 MHz, 
CDCl3) δ 7.95-7.88 (m, 2H), 7.61-7.54 (m, 2H), 6.28-6.19 (m, 1H), 6.19-6.07 (m, 
2H), 5.88-5.78 (m, 2H), 3.84 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 174.8, 165.2, 
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131.9, 131.4, 128.7, 128.2, 126.7, 126.5, 125.0, 124.1, 73.3, 73.1, 53.8; MS (EI) 
m/z (%) 249 (7), 201 (10), 182 (30), 152 (57), 120 (100); HRMS (EI) calcd for 
C15H13BrO5: 351.9946. Found 351.9935; Anal. Calcd for C15H13BrO5: C, 51.07; H, 
3.71. Found C, 50.73; H, 3.74. 
 
(–)-(1R,4S,5S,6S)-4,5,6-Trihydroxy-6-(methoxycarbonyl)cyclohex-2-en-1-yl 4-
bromobenzoate (91). 
 
The allylic alcohol 90 (335 mg, 0.949 mmol) was dissolved in CH2Cl2 (95 mL, 0.01 
M), then TMEDA (199 μL, 1.33 mmol) was added. The solution was cooled to –78 
°C and then OsO4 (250 mg, 0.983 mmol) in CH2Cl2 (1.5 mL) was added slowly to 
the reaction mixture. The clear solution turned a dark red upon complete 
addition of the osmium. After 1 h TLC indicated complete consumption of the 
starting material, so the CH2Cl2 was removed under reduced pressure. The 
residue was dissolved in THF (10 mL) and to this solution was added saturated 
NaHSO3 (10 mL). The mixture was then heated to reflux for 3 h. The solvents 
were removed under reduced pressure to provide a grey powder, which was 
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suspended in MeOH (40 mL) and subsequently filtered through a tightly packed, 
thin bed of Celite. The slightly yellow filtrate was concentrated under reduced 
pressure to provide a milky white residue which began to crystallize on standing. 
The residue was purified anyway by flash column chromatography 
[hexane/EtOAc (2:1 to 1:1 to 1:2)] to provide a glistening white foam (340 mg, 
0.883 mmol, 93% yield). 
91: Rf = 0.20 [hexane/EtOAc (1:2)]; mp 49-51 °C (EtOAc); [α]
20
𝐷
 = –251.3° (c = 0.3, 
acetone); IR (neat) ν 3500, 1720, 1676, 1587, 1261 cm–1; 1H NMR (600 MHz, 
Acetone-d6) δ 8.04 (d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 6.25 (d, J = 2.1 Hz, 
1H), 5.78 (dd, J = 10.5, 1.7 Hz, 1H), 5.66 (dt, J = 10.5, 1.9 Hz, 1H), 5.19 (s, 1H), 
4.56 (dt, J = 14.9, 7.4 Hz, 1H), 4.52 (d, J = 3.8 Hz, 1H), 4.24 (s, 1H), 4.04 (d, J = 8.7 
Hz, 1H), 3.69 (s, 3H); 13C NMR (151 MHz, Acetone-d6) δ 172.4, 164.8, 131.7, 
131.6, 131.3, 129.4, 127.7, 124.4, 78.4, 73.3, 70.9, 66.0, 51.9; MS (EI) m/z (%) 
267 (5), 199 (70), 184 (100), 154 (40); HRMS (EI) calcd for C13H12BrO5: 326.9868. 
Found 326.9979 (loss of methyl carboxylate); Anal. Calcd for C15H15BrO7: C, 
46.53; H, 3.90. Found C, 46.30; H, 4.12. 
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(–)-(1R,5R,6S)-5,6-Dihydroxy-6-(methoxycarbonyl)-4-oxocyclohex-2-en-1-yl 4- 
bromobenzoate (92). 
 
The triol 91 (55 mg, 0.142 mmol) was dissolved in dioxane (7 mL), DDQ (51 mg, 
0.227 mmol) was then added at once, and the mixture was heated at 70 °C for 6 
days. When the starting material was consumed, dioxane was removed under 
reduced pressure, then the mixture was dissolved in EtOAc (10 mL). The product 
was washed with saturated NaHSO3 (5 mL) and saturated NaHCO3 (5 mL) then 
dried over MgSO4 and filtered through Celite and concentrated under reduced 
pressure. The orange residue was purified by column chromatography 
[hexane/EtOAc (2:1 to 1:1 to 1:2)] to provide a white solid (45 mg, 0.117 mmol, 
82%). 
92: Rf = 0.75 [hexane/EtOAc (1:2)]; mp 81-82 °C (EtOAc); [α]
20
𝐷
 = –208.4° (c = 0.6, 
acetone); IR (neat) ν 3459, 2955, 1697, 1587, 1260, 1094 cm–1; 1H NMR (600 
MHz, Acetone-d6) δ 8.06 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 8.5 Hz, 2H), 6.91 (dd, J = 
10.3, 3.3 Hz, 1H), 6.35 (dd, J = 3.0, 1.5 Hz, 1H), 6.18 (d, J = 10.3 Hz, 1H), 5.51 (s, 
1H), 5.28 (d, J = 4.7 Hz, 1H), 4.37 (d, J = 4.3 Hz, 1H), 3.70 (s, 3H); 13C NMR (151 
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MHz, Acetone-d6) δ 205.5, 205.3, 205.2, 194.5, 170.7, 165.9, 164.6, 142.8, 131.8, 
131.8, 131.7, 131.4, 129.8, 128.9, 128.6, 127.9, 127.3, 79.7, 75.7, 69.8, 52.1; MS 
(EI) m/z (%) 383 (3), 265 (5), 199 (10), 184 (100), 154 (25), 125 (12); HRMS (EI) 
calcd for C13H10BrO5: 383.9845. Found 383.9835; Anal. Calcd for C15H13BrO7: C, 
46.78; H, 3.40. Found C, 46.49; H, 3.47. 
 
(–)-(1S,6R)-Methyl 6-((tert-Butyldimethylsilyl)oxy)-1-hydroxycyclohexa-2,4-
dienecarboxylate (93). 
 
The diene 55 (730 mg, 4.3 mmol) was dissolved in CH2Cl2 (22 mL) followed by the 
addition of imidazole (322 mg, 4.3 mmol) and DMF (5 mL). TBSCl (647 mg, 4.3 
mmol) was then added at once. The reaction was left to age 20 h. The reaction 
mixture was diluted with water (50 mL), and the organic layer collected. The 
aqueous layer was then extracted with CH2Cl2 (2 x 20 mL). The combined organic 
extracts were washed with 10% CuSO4 solution (50 mL), followed by brine (50 
mL), and then dried over MgSO4. The dry extract was filtered and concentrated 
under reduced pressure to provide a yellow oil. The oil was purified by gravity 
chromatography [hexane/EtOAc (5:1)] as a clear oil (500 mg, 1.75 mmol, 41%). 
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93: Rf = 0.25 [hexane/EtOAc (4:1)]; [α]
20
𝐷
 = –36.8° (c = 3.0, CH2Cl2); 1H NMR (300 
MHz, Acetone-d6) δ 6.11 (dd, J = 9.5, 5.2 Hz, 1H), 5.98-5.85 (m, 1H), 5.79 (dd, J = 
9.5, 1.0 Hz, 1H), 5.72-5.63 (m, 1H), 4.96 (s, 1H), 3.79 (s, 3H), 3.38 (s, 1H), 0.88 (s, 
9H), 0.10 (s, 3H), 0.02 (s, 3H); 13C NMR (151 MHz, Acetone-d6) δ 175.2, 131.9, 
126.6, 124.8, 122.5, 74.6, 72.7, 52.9, 25.6, 17.9, –4.4, –5.3. NMR data matched 
that reported by Lewis and co-workers.28 
 
(–)-(1S,2R,5S,6S)-Methyl 2-((tert-Butyldimethylsilyl)oxy)-1,5,6-
trihydroxycyclohex-3-enecarboxylate (94). 
 
The protected diene 93 (272 mg, 0.956 mmol) was dissolved in CH2Cl2 (90 mL, 
0.01 M) followed by the addition of TMEDA (0.15 mL, 1 mmol). The solution was 
cooled to –78 °C and then OsO4 (250 mg, 0.983 mmol) in CH2Cl2 (1.5 mL) was 
added slowly to the reaction mixture. The clear solution turned a dark red upon 
complete addition of the osmium. After 1 h TLC indicated complete consumption 
of the starting material, so the CH2Cl2 was removed under reduced pressure. The 
residue was dissolved in THF (10 mL) and to this solution was added saturated 
NaHSO3 (10 mL). The mixture was then heated to reflux for 3 h. The solvents 
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were removed under reduced pressure to provide a grey powder, which was 
suspended in MeOH (50 mL) and subsequently filtered through a tightly packed, 
thin bed of Celite. The slightly yellow filtrate was concentrated under reduced 
pressure to provide a milky white residue which began to crystallize on standing. 
The crude mixture was purified by flash chromatography [hexane/EtOAc (2:1)] to 
yield (70 mg, 0.231 mmol, 23%). 
94: Rf = 0.33 [hexane/EtOAc (1:1)] (KMnO4 stain); mp 108-110 °C (EtOAc); [α]
20
𝐷
 = 
–7.3° (c = 0.7, acetone); IR (neat) ν 3542, 3406, 2953, 2928, 2879, 2856, 1747, 
1663 cm–1; 1H NMR (300 MHz, Acetone-d6) δ 5.98 (dd, J = 9.8, 4.9 Hz, 1H), 5.67 
(d, J = 9.8 Hz, 1H), 4.32 (d, J = 9.8 Hz, 1H), 4.25 (q, J = 4.6 Hz, 1H), 4.19 (d, J = 4.6 
Hz, 1H), 3.85 (ddd, J = 9.8, 7.7, 4.4 Hz, 1H), 3.76 (s, 1H), 3.74 (s, 3H), 3.68 (d, J = 
7.7 Hz, 1H), 0.89 (s, 9H), 0.18 (s, 3H), 0.07 (s, 3H); 13C NMR (75 MHz, Acetone-d6) 
δ 173.8, 131.0, 128.5, 76.2, 72.7, 68.9, 66.9, 51.9, 25.5, 18.0, –4.4, –5.8; MS (EI) 
m/z (%) 261 (15), 225 (30), 197 (80), 155 (30), 75 (100); HRMS (EI) calcd for 
C14H26O6Si: 261.0794. Found 261.0802; Anal. Calcd for: C, 52.80; H, 8.23. Found 
C, 53.52; H, 8.40.  
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(–)-(1S,2R,6R)-Methyl 2-((tert-Butyldimethylsilyl)oxy)-1,6-dihydroxy-5-
oxocyclohex-3-enecarboxylate (95). 
 
The allylic triol 94 (20 mg, 66 µmol) was dissolved in dioxane, followed by the 
addition of DDQ (19.5 mg, 86 µmol). The yellow solution was held at 85 °C for 3 
days. The ketol 94 was isolated by preparative TLC (15 mg, 50 µmol, 75%). 
95: Rf = 0.75 [hexane/EtOAc (1:1)]; [α]
20
𝐷
 = –12.6° (c = 0.5, acetone); IR (neat) ν 
3494, 2955, 2858, 1754, 1693, 1249, 1120, 836cm–1; 1H NMR (300 MHz, Acetone-
d6) δ 6.90 (d, J = 9.9 Hz, 1H), 6.19 (d, J = 9.9 Hz, 1 H), 4.56 (s, 1H), 4.39 (d, J = 2.6 
Hz, 1H), 4.36 (t, J = 3.6 Hz, 1H), 4.17 (sext, J = 2.6 Hz, 1H), 3.79 (s, 3H), 0.87 (s, 
9H), 0.17 (s, 3H), 0.05 (s, 3H); 13C NMR (75 MHz, Acetone-d6) δ 198.1, 172.6, 
145.0, 128.8, 76.4, 75.5, 74.7, 52.5, 25.4, 17.9, –4.6, –6.1; MS (EI) m/z (%) 259 
(45), 241 (80), 213 (80), 209 (100), 181 (40), 75 (90); HRMS (EI) calcd for 
C14H24O6Si: 259.0638. Found 259.0650. 
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(+)-(1R,2R,6R)-Methyl 1,2,6-Trihydroxy-5-oxocyclohex-3-enecarboxylate (96). 
 
The ketol 95 (5 mg, 16 μmol) was dissolved in MeOH (0.5 mL). To this mixture 
was added AcOH (2 mg, 33 μmol, ~6 drops) and TBAF 1 M in THF (20 µL, 16 
µmol, ~5 drops). When starting material was consumed, the mixture was 
purified by preparative TLC, providing a yellow residue (2 mg, 9.9 µmol, 63%). 
96: Rf = 0.45 [EtOAc/MeOH/H2O (90:10:5)]; [α]
20
𝐷
 = +5.2° (c = 0.1, acetone); IR 
(neat) ν 3428, 2958, 1748, 1699, 1262, 1123 cm–1; 1H NMR (300 MHz, Acetone-
d6) δ 6.90 (d, J = 10.0 Hz, 1H), 6.18 (d, J = 10.0 Hz, 1H), 4.81 (d, J = 6.1 Hz, 1H), 
4.76 (s, 1H), 4.39 (dd, J = 10.2, 3.9 Hz, 1H), 4.31 (d, J = 4.0 Hz, 1H), 4.05 (dd, J = 
10.2, 5.9 Hz, 1H), 3.80 (s, 3H); 13C NMR (151 MHz, Acetone-d6) δ 197.9, 172.7, 
144.6, 128.9, 75.0, 74.7, 74.6, 52.4.  
 
(+)-(1R,2R,6R)-1,2,6-Trihydroxy-5-oxocyclohex-3-enecarboxylic acid (79). 
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The enone triol 96 (2 mg) was dissolved in water (0.3 mL), and Ba(OH)2·8H2O (5 
mg) was added. The mixture was refluxed for 2 h. NaHSO4 was added and the 
suspension was filtered. The aqueous mixture was extracted with Et2O (5 mL). 
Both the organic extract and the aqueous mixture were concentrated under 
reduced pressure. Both residues were purified by preparative TLC 
[EtOAc/MeOH/H2O (90:10:5)]. The reaction condition seemed to have 
decomposed all organic materials present. No compounds were identified. 
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